×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Module 4: Phase 2 – Preliminary Human Efficacy and Safety (continued)
Session Chair(s)
Stephen V. O'Quinn, PharmD
President
Perissos, Inc., United States
- End of Phase 2 Meeting
- Special Protocol Assessment (SPA)
- Phase 3 Decision
Have an account?